Delving into the Latest Updates on Ciprofloxacin with Synapse

Overview

Basic Info

SummaryCiprofloxacin is a fluoroquinolone antibiotic used to treat a number of bacterial infections. It can be taken by mouth, as eye drops, as ear drops, or intravenously. It is a second-generation fluoroquinolone with a broad spectrum of activity that usually results in the death of the bacteria. Ciprofloxacin was patented in 1980 and introduced in 1987. It is on the World Health Organization's List of Essential Medicines. The World Health Organization classifies ciprofloxacin as critically important for human medicine. It is available as a generic medication.Common side effects include nausea, vomiting, and diarrhea. Severe side effects include an increased risk of tendon rupture, hallucinations, and nerve damage.

Drug Type

Small molecule drug

Synonyms

Ciprfloxacin Lactate and Sodium Chloride, Ciprofioxacin Lactate, Ciprofloxacin (JP17/USP/INN)

+ [29]

Target

Bacterial Top II

Action

inhibitors

Mechanism

Bacterial DNA gyrase inhibitors(Bacterial DNA gyrase inhibitors)

Therapeutic Areas

Infectious DiseasesDigestive System DisordersOtorhinolaryngologic Diseases+ [4]

Active Indication

Gram-Negative Bacterial InfectionsSepsisPlague+ [26]

Inactive Indication

Acute otitis externaChronic disease of respiratory systemChronic lower urinary tract infection+ [10]

Originator Organization

Meiji Seika Pharma Co., Ltd.

Active Organization

Bayer HealthCare Pharmaceuticals, Inc.

Bayer Yakuhin Ltd.

Meiji Seika Pharma Co., Ltd.

+ [3]

Inactive Organization

Bayer AG

Novartis Pharmaceuticals Corp.

Novartis AG

+ [4]

License Organization

ALK-Abello A/S

Otonomy, Inc.ALK-Abelló Arzneimittel GmbH

+ [3]

Drug Highest PhaseApproved

First Approval Date

Japan (01 Jan 1987),

Bacterial Infections

RegulationAccelerated Approval (United States), Orphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC17H18FN3O3

InChIKeyMYSWGUAQZAJSOK-UHFFFAOYSA-N

CAS Registry85721-33-1

Pseudomonas aeruginosa is a multidrug-resistant (MDR) pathogen, and efflux pumps such as MexCD-OprJ and MexEF-OprN play a key role in its antibiotic resistance. This study evaluated the putative effects of curcumin and methanolic extracts of F. excelsior L. and G. glabra L. on the expression of these efflux pumps, as well as their role in mediating antibiotic resistance.

METHODS AND RESULTS:

In this study, MDR P. aeruginosa clinical strains were used to determine the minimum inhibitory concentrations (MICs) of tobramycin and ciprofloxacin in the presence and absence of curcumin and selected plant extracts (F. excelsior L. and G. glabra L.) and curcumin. Real-time PCR was used to assess changes in efflux pump gene expression in tested strains. A significant positive correlation was identified between resistance to the tested antibiotics and increased expression of MexCD-OprJ and MexEF-OprN, as determined by Spearman's rank correlation using SPSS (p < 0.05). Treatment with the extracts, individually and in combination, resulted in a reduction in the expression levels of both efflux genes (p < 0.05), with the combined treatment showing the greatest effect. These findings were supported by colony count and turbidity assays, as evidenced by > 80% reduction in viable counts and decreased turbidity in treated groups.

CONCLUSION:

Overexpression of MexCD-OprJ and MexEF-OprN is a key factor contributing to MDR in P. aeruginosa. Treatment with curcumin, F. excelsior L. and G. glabra L. extracts-especially in combination, suggesting potential for suppression of efflux gene expression and enhanced antibiotic efficacy.

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Prevalence of quorum sensing luxS gene in multidrug resistant uropathogens

Article

Author: Ghosh, Soham ; Kotturu, Sandeep Kumar ; Pradhan, Shilpa ; Lakshmi, Swarajya ; Mukhopadhyay, Sangita

BACKGROUND:

The increasing prevalence of antimicrobial resistance (AMR) among urinary tract infections (UTIs) is making clinical management challenging. Biofilm formation is a key mechanism contributing to antibiotic resistance in uropathogens. Quorum sensing is known to regulate several bacterial processes like bioluminescence, virulence, and biofilm formation which is known to play a role in the development of drug resistance. Out of three major quorum sensing systems, luxS/AI-2 is a universal system used by both Gram-positive and Gram-negative bacteria.

METHODS:

Community-acquired AMR UTI isolates were analyzed for bacterial species distribution and antibiotic susceptibility patterns. Phenotypic biofilm formation was assessed using Congo Red Agar (CRA) method. The presence of luxS gene, associated with the AI-2 quorum sensing system, was determined by polymerase chain reaction (PCR).

RESULTS:

Eight different bacterial species were identified, with Escherichia coli (44.1%) being the most prevalent, followed by Klebsiella spp. (27.9%). More than 90% of the isolates were resistant to at least 3 antibiotics and resistance to ampicillin was most common (67.6%), followed by cefazolin (54.4%), amoxyclav (53.4%), aztreonam (52.9%), and ciprofloxacin (48.52%). Phenotypic biofilm formation was observed in 35.29% of the AMR isolates which produced characteristic black colonies. However, luxS gene was detected in 91.17% of these AMR isolates.

CONCLUSION:

Higher prevalence of luxS gene in AMR isolates indicate a strong association of quorum sensing potential with development of multidrug resistance. Targeting quorum sensing pathways may represent potential adjunct therapy alongside antibiotics for efficient clinical management of multidrug resistant UTI cases.

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Phenotypic and genomic characterization of antimicrobial resistance in vancomycin-resistant Enterococcus faecalis

Article

Author: Tyagi, Anuj ; Gill, Jatinder Paul Singh ; Kaur, Simranpreet ; Singh, Randhir ; Parmar, Neha ; Arora, Anil Kumar

BACKGROUND:

Enterococcus faecalis has emerged as a significant nosocomial pathogen with increasing relevance at the human-animal interface. This study investigated the antimicrobial resistance (AMR) profiles and genomic characteristics of E. faecalis isolated from cattle farms in Punjab, India.

METHODS AND RESULTS:

A total of 288 samples, comprising cattle feces (239), cattle handler hand swabs (34), and handler stool samples (15), were processed using standard bacteriological protocols. Presumptive isolates were confirmed as E. faecalis by culture characteristics and Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS). Antimicrobial susceptibility testing (AST) was performed using the Kirby-Bauer disk diffusion method, and vancomycin resistance was confirmed by minimum inhibitory concentration (MIC) testing. Resistance genes were screened by polymerase chain reaction (PCR) and vancomycin-resistant isolates underwent whole-genome sequencing (WGS) for detailed genomic characterization. Overall, 51 E. faecalis isolates were recovered from 288 samples, yielding an overall prevalence of 17.70% (51/288). Sample-wise prevalence was 19.24% (46/239) in cattle feces, 8.82% (3/34) in hand swabs, and 13.33% (2/15) in stool samples. AST revealed high resistance rates to erythromycin (72.54%), linezolid (31.37%), ciprofloxacin and penicillin G (29.41% each), and tetracycline (27.45%). Phenotypic vancomycin resistance was identified in 5.88% (3/51) of isolates. PCR screening detected vanC1 in 31.37% and vanC2/C3 in 33.33% of isolates, although their presence was not uniformly associated with phenotypic resistance.WGS of three vancomycin-resistant E. faecalis isolates identified resistance genes, virulence determinants, and a shared multilocus sequence type (MLST), ST-387, among isolates from cattle and handlers.

CONCLUSIONS:

These findings highlight cattle farms as reservoirs of multidrug resistant (MDR) and virulent E. faecalis strains, emphasizing the importance of genomic surveillance to prevent the dissemination of these strains into healthcare settings.

175

News (Medical) associated with Ciprofloxacin

11 Jun 2026

·www.prnewswire.com

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in Japan, Brazil, Australia and the United States Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC CAMBRIDGE, Mass., June 11, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Korean Intellectual Property Office (KIPO) has issued Korean Patent Number 10-2969898 covering the composition of PrimeC, the Company's lead drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). The granted patent claims cover key aspects of PrimeC, including its proprietary tablet formulation, manufacturing process, pharmacokinetic characteristics, and pharmaceutical use for the treatment of ALS. The patent is expected to provide patent protection for such aspects of PrimeC in South Korea through 2042. "This patent grant further strengthens our growing global intellectual property estate surrounding PrimeC," said Alon Ben-Noon, Chief Executive Officer of NeuroSense. "South Korea is an important pharmaceutical market, and this milestone reflects the continued recognition of the novelty and proprietary nature of PrimeC as we advance toward Phase 3 development." The South Korean patent grant follows patent grants received in other major jurisdictions, further expanding NeuroSense's global intellectual property portfolio and supporting the long-term development and commercialization strategy for PrimeC. PrimeC is a novel oral therapy designed to simultaneously target multiple biological mechanisms associated with ALS progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism. NeuroSense previously reported compelling results from its Phase 2b PARADIGM study, including meaningful slowing of disease progression, significant biological activity across multiple ALS-related biomarkers, including microRNAs, and long-term data demonstrating a meaningful survival benefit. The Company has received clearance from the U.S. Food and Drug Administration (FDA) to initiate its pivotal Phase 3 PARAGON study in ALS. About NeuroSense NeuroSense Therapeutics is a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company's lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism. NeuroSense has generated compelling clinical data from its Phase 2b PARADIGM study in ALS, demonstrating meaningful slowing of disease progression. The Company also reported significant biological activity across multiple biomarkers associated with ALS, including microRNAs, supporting PrimeC's multi-target mechanism of action. Notably, long-term follow-up data indicated a meaningful survival benefit, representing a potentially important advancement in the treatment of ALS. NeuroSense has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a pivotal Phase 3 clinical trial (PARAGON) in ALS, which is expected to enroll approximately 300 participants, primarily in the United States. For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels. About PrimeC PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD. About ALS Amyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU. Forward-Looking Statements This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements, including statements regarding the benefits of the Korean patent, development, regulatory progress and potential commercialization of PrimeC, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding the benefits of the Korean patent; outcomes and the timing of current and future clinical trials; timing for reporting data, including from the study of PrimeC in Alzheimer's disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2026 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law. SOURCE NeuroSense 21% more press release views with Request a Demo

Phase 2Phase 3Clinical Result

09 Jun 2026

·www.prnewswire.com

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patents CAMBRIDGE, Mass., June 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Japan Patent Office has issued a Japanese Patent 7857044 covering the Company's lead drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). The patent, entitled "Compositions comprising ciprofloxacin and celecoxib," includes 17 claims and provides protection through 2042 for the unique formulation and manufacturing process of PrimeC, including its synchronized delivery profile of celecoxib and ciprofloxacin, designed to target multiple key mechanisms underlying ALS progression. "This patent grant further strengthens our global intellectual property estate around PrimeC and reinforces the novelty of our synchronized extended-release formulation," said Alon Ben-Noon, Chief Executive Officer of NeuroSense. "Japan is a key pharmaceutical market, and this patent further supports our long-term commercialization strategy as we advance PrimeC toward a pivotal Phase 3 clinical trial." The patent is part of NeuroSense's broader global IP portfolio protecting both the composition and formulation of PrimeC, which is designed to modulate multiple disease-relevant mechanisms, including neuroinflammation, iron dysregulation, autophagy, and miRNA pathways. PrimeC has demonstrated consistent clinical, biomarker, and survival benefit in the Phase 2b PARADIGM study, including a significant survival benefit in extended follow-up analyses. The Company has received FDA's clearance to proceed and is preparing for initiation of a Phase 3 pivotal study (PARAGON). The Japanese patent is expected to provide long-term protection for PrimeC's proprietary formulation in a key strategic market, subject to standard terms and potential extensions. About NeuroSense NeuroSense Therapeutics is a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company's lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism. NeuroSense has generated compelling clinical data from its Phase 2b PARADIGM study in ALS, demonstrating meaningful slowing of disease progression. The Company also reported significant biological activity across multiple biomarkers associated with ALS, including microRNAs, supporting PrimeC's multi-target mechanism of action. Notably, long-term follow-up data indicated a meaningful survival benefit, representing a potentially important advancement in the treatment of ALS. NeuroSense has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a pivotal Phase 3 clinical trial (PARAGON) in ALS, which is expected to enroll approximately 300 participants, primarily in the United States. For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels. About PrimeC PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD. About ALS Amyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU. Forward-Looking Statements This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements, including statements regarding the benefits of the Japanese patent, development, regulatory progress and potential commercialization of PrimeC, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding the benefits of the Japanese patent; outcomes and the timing of current and future clinical trials; timing for reporting data, including from the study of PrimeC in Alzheimer's disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2026 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law. SOURCE NeuroSense 21% more press release views with Request a Demo

Phase 2Phase 3Clinical Result

28 May 2026

·www.cidrz.org

Advancing Sexual and Reproductive Health Research in Zambia.

Our RMNCH department recently held a stakeholder dissemination meeting to share key findings from our STI research portfolio. The meeting brought together a strong coalition of partners including ZNPHI, NAC, UNZABREC, NHRA, GARDP, CHAI, UNICEF, Evidence Action and many others whose engagement is essential to turning evidence into policy and programs that improve the health and well-being of Zambians. CT/NG Burden in Priority Populations in Lusaka, Zambia: Implications for STI Screening and AMR Surveillance In the largest prevalence study conducted in Zambia among pregnant women, adolescents, and key populations (KP), we found that NG prevalence was up to 3X higher while CT aligned with regional estimates with KPs bearing the highest burden. Additionally, NG isolates showed resistance to Ciprofloxacin and Tetracycline. These findings make a compelling case for routine point-of-care NAAT-based screening and for integrating AMR surveillance into Zambia’s national STI programs. Progression and Regression of Cervical Precancer among Women Living with HIV in Zambia A longitudinal follow-up of 241 women living with HIV showed that high-risk HPV prevalence and high-grade cervical disease decreased over time. Precancer treatment was strongly associated with disease regression, yet not all treatment was effective, underscoring the need for better biomarkers to guide decisions and reduce overtreatment. 2025 Zambia Comprehensive Facility Survey: National Evaluation of the Maternal HIV/Syphilis Dual Testing Program This survey assessed syphilis screening and treatment at ANC facilities nationwide. After Ministry of Health trained 23,000+ health workers across 3,100+ facilities, national syphilis screening coverage rose from 46% in 2023 to 87% in 2025, approaching the 95% WHO screening target. Syphilis treatment coverage stood at approximately 90% among trained facilities. Key gaps remain in provider counselling knowledge, stock continuity, and data quality.

100 Deals associated with Ciprofloxacin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00186	Ciprofloxacin	S01AE03 J01MA02 S03AA07	DB00537

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Gram-Negative Bacterial Infections	Australia	Demo S.A. Pharmaceutical Industry	04 May 2026
Sepsis	Australia	Demo S.A. Pharmaceutical Industry	04 May 2026
Otitis Externa	United States	ALK-Abello A/S	10 Dec 2015
Otitis Media With Effusion	United States	ALK-Abello A/S	10 Dec 2015
Hospital-acquired pneumonia	United States	Bayer HealthCare Pharmaceuticals, Inc.	02 Feb 2015
Non-complicated skin and skin structure infection	United States	Bayer HealthCare Pharmaceuticals, Inc.	02 Feb 2015
Plague	United States	Bayer HealthCare Pharmaceuticals, Inc.	02 Feb 2015
Bronchiectasis	China	Bayer Pharma AG	22 Sep 2013
Bacterial prostatitis	Australia	Ipca Pharma (Australia) Pty Ltd.	05 Nov 2004
Bronchial Diseases	Australia	Ipca Pharma (Australia) Pty Ltd.	05 Nov 2004
Gastroenteritis	Australia	Ipca Pharma (Australia) Pty Ltd.	05 Nov 2004
Gonococcal urethritis	Australia	Ipca Pharma (Australia) Pty Ltd.	05 Nov 2004
Uterine Cervicitis	Australia	Ipca Pharma (Australia) Pty Ltd.	05 Nov 2004
Pyelonephritis	United States	Bayer HealthCare Pharmaceuticals, Inc.	25 Mar 2004
Anthrax	Japan	Bayer Yakuhin Ltd.	21 Dec 2001
Cholangitis	Japan	Bayer Yakuhin Ltd.	22 Sep 2000
Cholecystitis	Japan	Bayer Yakuhin Ltd.	22 Sep 2000
Peritonitis	Japan	Bayer Yakuhin Ltd.	22 Sep 2000
Pneumonia	Japan	Bayer Yakuhin Ltd.	22 Sep 2000
Complicated urinary tract infection	United States	Bayer HealthCare Pharmaceuticals, Inc.	26 Sep 1997

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute otitis externa	Phase 3	United States	Otonomy, Inc.	01 Jun 2016
Acute otitis externa	Phase 3	Canada	Otonomy, Inc.	01 Jun 2016
Infective otitis externa	Phase 3	United States	Otonomy, Inc.	01 Jun 2016
Infective otitis externa	Phase 3	Canada	Otonomy, Inc.	01 Jun 2016
Otitis Media	Phase 3	United States	Otonomy, Inc.	01 Oct 2015
Non-cystic fibrosis bronchiectasis	Phase 3	United States	Novartis AG	02 May 2013
Non-cystic fibrosis bronchiectasis	Phase 3	United States	Bayer AG	02 May 2013
Non-cystic fibrosis bronchiectasis	Phase 3	Japan	Novartis AG	02 May 2013
Non-cystic fibrosis bronchiectasis	Phase 3	Japan	Bayer AG	02 May 2013
Non-cystic fibrosis bronchiectasis	Phase 3	Argentina	Bayer AG	02 May 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01243437 (CTgov)	Phase 2	Plague	5	ciprofloxacin	dikcefyinj = zgeywcftfn izevcfvrym (ktmwuopewa, wbatfodzpj - nanmgnlxvf) View more	-	03 Jun 2026
NCT06728072 (ASCO2026)	Phase 2	Metastatic Colorectal Carcinoma First line	44	chemotherapy + MBMT (ciprofloxacin, metronidazole, +/- aspirin)	eegrbuegex(vraljbvptj) = nupniyhdlr thvfjkqwfb (wvbcfrhyxm )	Positive	29 May 2026
NCT05977868 (COPAT, CTgov)	Phase 4	Bone and joint infections \| Genitourinary tract infection \| Infection of digestive system ... View more	94	cefalexin+levofloxacin+Amoxicillin+doxycycline+delafloxacin+linezolid+amoxicillin-clavulanate+ciprofloxacin+cefpodoxime+cefadroxil (Group 1 (Experimental))	cucbsjabdd = zuqvnsxrau byfihmkpmn (yqrbfuevcw, wtlqexpvaq - wvqybgqyqr) View more	-	26 Aug 2025
				cefazolin+ceftazidime-avibactam+dalbavancin+ampicillin-sulbactam+ceftaroline+ceftazidime+Ampicillin+cefepime+daptomycin+ertapenem (Group 2 (Control))	cucbsjabdd = aprwyjnbfb byfihmkpmn (yqrbfuevcw, wvbzwldekv - mdlotlrnkd) View more
NCT03850379 (Pubmed \| Int J Infect Dis)	Phase 2	Hematopoietic stem cell transplantation	308	Ciprofloxacin	ylvjozgoyt(duruwtadye) = jxkqdkwsoo jfupjkmiwl (bynebaiuzo ) View more	Positive	15 Jul 2024
				Levofloxacin	ylvjozgoyt(duruwtadye) = josybgwhhz jfupjkmiwl (bynebaiuzo ) View more
NCT02773732 (phase 1b, Pubmed)	Phase 1	Refractory acute myeloid leukemia	11	Ciprofloxacin 750 mg	ysbzvyminm(vgoohykgvm) = gqlonulzrl bdmfeljcrn (kxfdjimvtz ) View more	Negative	06 Jun 2024
				Ciprofloxacin 1000 mg	ysbzvyminm(vgoohykgvm) = xadaihbfdk bdmfeljcrn (kxfdjimvtz ) View more
NCT03969758 (clinicaltrials.gov PRS ID: NCT03969758, 31/05/2019, Pubmed)	Phase 3	Liver Abscess	140	Ciprofloxacin	lsrhroqasn(qwlmoydgae) = lgyrdkdjck bsjwipqiut (fmkwwqtmmp ) View more	Positive	20 May 2024
				Cefixime	lsrhroqasn(qwlmoydgae) = qfhanuprxd bsjwipqiut (fmkwwqtmmp ) View more
NCT03850379 (not available, Tandem Meetings ASTCT and CIBMTR2023)	Phase 2	Hematopoietic stem cell transplantation	-	Ciprofloxacin	pjriazvyny(udkillroua) = axzhrpwmss wenpaxagmw (dpmcznjxlw ) View more	Positive	01 Feb 2023
				Levofloxacin	pjriazvyny(udkillroua) = lvkthyixsd wenpaxagmw (dpmcznjxlw ) View more
NCT01265173 (Pubmed \| Am J Gastroenterol)	Not Applicable	Spontaneous bacterial peritonitis First line	261	Cefotaxime	onkhdxiocg(ohcvwqoldo) = ytydjbzokl qflnbpenpm (mfrrlznmcm )	-	02 Jan 2023
				Ceftriaxone	onkhdxiocg(ohcvwqoldo) = tmrzhjlifh qflnbpenpm (mfrrlznmcm )
NCT05436678 (Biospace) Manual	Phase 1	Amyotrophic Lateral Sclerosis	20	Celecoxib+Ciprofloxacin+Ciprofloxacin+Celecoxib	ggqqqzrpdv(dkttuthxsl) = as a comparison of PrimeC to ciprofloxacin and celecoxib shows that the AUC0-t, and AUC0-∞ are lower for both components of PrimeC compared to the highest approved doses of each of the components administered separately. noplrityti (picndhqnmd ) View more	Positive	28 Sep 2022
NCT02773732 (UF-AML-CE-101 \| phase 1b, CTgov)	Phase 1/2	Refractory acute myeloid leukemia	11	Etoposide+Ciprofloxacin 1000 MG (Ciprofloxacin Dose Level +1)	qkvbzdrzyc = tvoxtynkpo wslkxlvzls (zivjkmosep, cighzjnnky - wlhyflqgxb) View more	-	05 Aug 2022
				Etoposide+Ciprofloxacin 750 MG (Ciprofloxacin Dose Level 0)	ljrwybkjvk(iftlrcwoev) = ygwhnvgjzx nwhfjiiwza (znsmrekmbe, dhevykapfj - lnrzpdxtta) View more